Maintenance doses range from 0.5 mg to 2.0 mg weekly (Ozempic) for diabetes and up to 2.4 mg weekly (Wegovy) for weight management
Injecting into fatty tissue rather than muscle is essential because it provides a more consistent absorption rate
Importantly, these mechanistic hypotheses are supported by evidence from large, randomised controlled trials, which has demonstrated that GLP-1RAs reduced major adverse cardiovascular events (MACE), including myocardial infarction, stroke and cardiovascular death, particularly in high-risk individuals such as those with type 2 diabetes mellitus
NCT06822517 Dapansutrile (Olatec Therapeutics) is currently being studied in a Phase 2 trial Why Its Exciting: If chronic neuroinflammation truly fuels disease progression, NLRP3 blockade could offer a wholly new disease-modifying strategy
To learn more about our approach, visit our Semaglutide service page or explore our educational Semaglutide resources